The Efficacy and Safety of Imeglimin as Add-On Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy

被引：0
|
作者：
Fouqueray, Pascale
Pirags, Valdis
Inzucchi, Silvio
Bailey, Clifford J.
Schernthaner, Guntram
Diamant, Michaela
Lebovitz, Harold E.
机构：
来源：
DIABETES | 2012年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1004-P
引用
收藏
页码：A257 / A257
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of ertugliflozin in patients with type 2 diabetes inadequately controlled with metformin monotherapy: VERTIS MET trial
    Charbonnel, B.
    Pascu, R.
    Frias, J.
    Pall, D.
    Saur, D.
    Darekar, A.
    Huyck, S.
    Shi, H.
    Lauring, B.
    Terra, S.
    Rosenstock, J.
    DIABETOLOGIA, 2017, 60 : S406 - S407
  • [22] SAFETY AND EFFICACY OF SITAGLIPTIN COMPARED WITH GLIMEPIRIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED WITH METFORMIN MONOTHERAPY
    Abrar, Amjad
    Khan, Shimal
    Rehman, Mehboob Ur
    Jan, Tehmina
    Faisal, Muhammad
    GOMAL JOURNAL OF MEDICAL SCIENCES, 2013, 11 (01): : 3 - 7
  • [23] Efficacy and safety of acarbose in patients with type 2 diabetes inadequately controlled with metformin
    Magner, J
    Taylor, T
    Krol, A
    Rosenstock, J
    DIABETOLOGIA, 1998, 41 : A231 - A231
  • [24] Efficacy and safety of saxagliptin plus metformin versus acarbose plus metformin in type 2 diabetes patients inadequately controlled with metformin monotherapy
    Du, J.
    Liang, L.
    Fang, H.
    Xu, F.
    Li, W.
    Shen, L.
    Mu, Y.
    DIABETOLOGIA, 2016, 59 : S372 - S372
  • [25] Efficacy and safety of acarbose in patients with type 2 diabetes inadequately controlled with metformin
    Rosenstock, J
    Magner, J
    Krol, A
    Taylor, T
    DIABETES, 1998, 47 : A351 - A351
  • [26] Efficacy and safety of efsubaglutide alfa as add-on to metformin in patients with type 2 diabetes
    Wang, Q.
    Bao, Y.
    Chen, S.
    Zhou, J.
    Anwar, D.
    Jia, W.
    DIABETOLOGIA, 2024, 67 : S358 - S358
  • [27] Dapagliflozin as Add-On Therapy in Asian Patients with Type 2 Diabetes Inadequately Controlled on Insulin
    Yang, Wenying
    Ma, Jianhua
    Li, Yiming
    Li, Yanbing
    Zhou, Zhiguang
    Kim, Jae Hyeon
    Zhao, June
    Ptaszynska, Agata
    DIABETES, 2017, 66 : A338 - A338
  • [28] A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus
    Shestakova, Marina V.
    Wilding, John P. H.
    Wilpshaar, Wim
    Tretter, Reiner
    Orlova, Valeria L.
    Verbovoy, Andrey F.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2018, 146 : 240 - 250
  • [29] Dual add-on therapy of gemigliptin and dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin alone: The SOLUTION 2 study
    Han, Kyung Ah
    Hwang, You-Cheol
    Moon, Shin Je
    Cho, Ho Chan
    Yoo, Hye Jin
    Choi, Sung Hee
    Chon, Suk
    Kim, Kyoung-Ah
    Kim, Tae Nyun
    Kang, Jun Goo
    Park, Cheol-Young
    Won, Jong Chul
    Cho, Eunjoo
    Kim, Jeongyun
    Park, Kyong Soo
    DIABETES OBESITY & METABOLISM, 2024, 26 (09): : 3743 - 3752
  • [30] Efficacy and safety of pioglitazone add-on in patients with type 2 diabetes inadequately controlled with metformin and dapagliflozin: a randomised, double-blind, and placebo-controlled study
    Cho, Y.
    Kim, K. -S.
    Lee, B. -W.
    Hong, J.
    Yu, J.
    Lim, S.
    Kim, Y.
    Lee, C.
    Kim, S.
    Kwak, S.
    Lee, W.
    DIABETOLOGIA, 2024, 67 : S322 - S323
12345